Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Mismatch-repair-deficient endometrial cancer
What changed

Mismatch-repair-deficient endometrial cancer

What changed: Mismatch-repair-deficient endometrial cancer

Cancer page →

Every dated change on the records linked to Mismatch-repair-deficient endometrial cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Trial result5Milestone6This record1On Edge

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordMismatch-repair-deficient endometrial cancer
Facts on this page last checked
When this page itself was last checked or edited.

2024 · 1

2024MilestoneStudy of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
KEYNOTE-B21: adjuvant pembrolizumab misses its primary endpoint overall; dMMR subgroup appears to benefit
A milestone in how this cancer is treated.

2023 · 5

2023Trial resultDUO-E / GOG-3041 / ENGOT-EN10
DUO-E / GOG-3041 / ENGOT-EN10 reported
PFS HR 0.
2023Trial resultNRG-GY018 / KEYNOTE-868
NRG-GY018 / KEYNOTE-868 reported
PFS HR 0.
2023Trial resultRUBY / ENGOT-EN6 / GOG-3031
RUBY / ENGOT-EN6 / GOG-3031 reported
OS 44.
2023MilestoneDUO-E / GOG-3041 / ENGOT-EN10
DUO-E: durvalumab with chemotherapy, PFS hazard ratio 0.42 in dMMR tumours
A milestone in how this cancer is treated.
2023MilestoneRUBY / ENGOT-EN6 / GOG-3031
RUBY and NRG-GY018: chemo-immunotherapy first line, PFS hazard ratios 0.28 and 0.30 in dMMR tumours
A milestone in how this cancer is treated.

2021 · 1

2021MilestoneDostarlimab
Dostarlimab approved for recurrent dMMR endometrial cancer after GARNET
A milestone in how this cancer is treated.

2020 · 1

2020Trial resultGARNET
GARNET reported
Dostarlimab produced durable objective responses in roughly four in ten patients with mismatch repair-deficient recurrent endometrial cancer; accelerated approval in April 2021.

2018 · 1

2018Trial resultPORTEC-3
PORTEC-3 reported
5-year OS 81.

2017 · 1

2017MilestonePembrolizumab
Pembrolizumab: first tumour-agnostic approval, for mismatch-repair-deficient tumours
A milestone in how this cancer is treated.

2013 · 1

2013MilestoneEndometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP)
TCGA describes the hypermutated MSI class of endometrial cancer
A milestone in how this cancer is treated.